Published
Semax and Selank are different research peptides, with different molecular backgrounds and different clinical questions in the studies reviewed here. Similar names and overlapping “nootropic” descriptions do not make them interchangeable. A useful comparison starts with identity, the population studied and the outcome measured, rather than a claim that one is universally better.
This guide compares selected evidence and documentation questions. It does not recommend either material for treating anxiety, improving concentration or combining with medication.
Are Semax and Selank the same peptide?
No. A primary Semax research report identifies it as ACTH(4–7)PGP, an ACTH-related construct. A separate primary Selank report identifies the tuftsin analogue sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. These are different identities, even though both names appear in discussions of neurological research. Semax: identity in a primary rat study; Selank: identity in a primary rat study.
Neither structural relationship tells you that the molecule reproduces every action of its parent peptide. Keep a compound’s identity separate from the biological effect someone attributes to it.
| Check | Semax | Selank |
|---|---|---|
| Molecular background | ACTH-related construct | Tuftsin analogue |
| Human source discussed below | Post-stroke rehabilitation study | Anxiety/neurasthenia comparison and an anxiety add-on study |
| Examples of measured outcomes | Plasma BDNF, motor performance and functional scores | Symptom scales and other study-specific assessments |
| Key comparison limit | These are different study settings, not a direct Semax-versus-Selank trial. | |
What is the difference between the human Semax and Selank studies?
A Semax report examined 110 people after ischemic stroke, grouped by rehabilitation timing and Semax exposure. The authors reported changes in plasma BDNF and functional outcomes. The abstract does not describe a blinded randomized allocation, and rehabilitation timing is part of the comparison. This is evidence about a particular post-stroke setting, not a trial of everyday focus in healthy people. Semax rehabilitation study: PubMed abstract.
One Selank report compared 30 patients receiving Selank with 32 receiving medazepam in generalized anxiety disorder and neurasthenia. The abstract reported similar anxiolytic effects and additional symptom differences. Its limited reporting does not establish broad equivalence, long-term safety or a comparison with Semax. Selank/medazepam comparison: PubMed abstract.
A second Selank report compared phenazepam alone in 30 patients with phenazepam plus Selank in 40. The authors reported earlier changes on one symptom scale and differences in selected undesirable effects. Because it examines an add-on treatment, it does not isolate Selank used alone. Selank add-on study: PubMed abstract.
These are summaries of the retrieved abstracts, not independent reanalyses of patient data. The Semax evidence profile and Selank evidence profile retain further study-specific context.
Does this show Semax is better for focus and Selank is better for anxiety?
The selected studies cannot establish that simple ranking. The interventions, participants, comparisons and outcomes differ. Improvement on a functional scale after stroke is not interchangeable with a change on an anxiety scale, and neither automatically measures concentration during ordinary work or study.
Someone places a favorable result from a stroke study beside a favorable result from an anxiety study, then calls the larger-looking change the “stronger peptide.” The scales may measure different things, use different ranges and involve different patients.
Before comparing the numbers, ask whether they answer the same question. If not, keep the studies in separate rows instead of manufacturing a winner.
Also separate a mechanistic measurement from a demonstrated outcome. A BDNF measurement does not itself prove better memory, and a neurotransmission-related observation does not establish every promoted anxiety or performance claim. Use the evidence-reading guide to keep the model and endpoint visible.
Are N-acetyl or amidated versions interchangeable with ordinary Semax or Selank?
Do not assume that a modified label refers to the same material as the preparation in a paper. Record the complete name and documented structure, including any stated terminal modification. Then match that form to the source actually being cited. A familiar base name is not enough to transfer a study’s findings to a different named form.
This guide does not rank modified versions by potency, duration or absorption. Such a ranking would need appropriate comparative evidence for the exact materials, conditions and outcomes. Customer experiences and a longer chemical name do not supply that comparison.
What should I compare when reading about Semax versus Selank?
- Identity: exact compound, sequence or supported identity specification, and any modification.
- Study setting: cells, animals, a defined patient group or healthy volunteers.
- Comparison: placebo, an active treatment, another care regimen or an add-on design.
- Outcome: the actual symptom scale, functional measure or biomarker, with its timeframe.
- Limitations: allocation, masking, concurrent treatment, sample size and what the source leaves unreported.
- Product evidence: documentation for the offered material, kept separate from the clinical study.
The store lists Semax 10 mg and Selank 10 mg as separate research materials. Matching labeled masses do not establish equivalent biological activity or suitability for human use. Request available item documentation through Lab Testing; a study on a named peptide does not verify a particular catalog lot.
Sources checked October 22, 2026. The worked comparison is fictional. This is an evidence-reading and identity comparison, not a treatment, combination or administration protocol. Store materials are for in-vitro laboratory research only.